New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 23, 2014
06:00 EDTCLVSClovis announces first patient enrolled in TIGER2 study
Clovis Oncology announced that the TIGER2 study has commenced with the dosing of the first patient at a U.S. study site. CO-1686 is the Company’s novel, oral, targeted covalent inhibitor of mutant forms of the epidermal growth factor receptor for the treatment of non-small cell lung cancer in patients with initial activating EGFR mutations as well as the dominant resistance mutation T790M.
News For CLVS From The Last 14 Days
Check below for free stories on CLVS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 10, 2014
16:03 EDTCLVSClovis announces first patient enrolled in lucitanib Phase 2 study
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use